טוען...
Cross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2
There is currently a lack of biological tools to study the replication cycle and pathogenesis of SARS-CoV-2, the etiological agent of COVID-19. Repurposing the existing tools, including antibodies of SARS-CoV, is an effective way to accelerate the development of therapeutics for COVID-19. Here, we e...
שמור ב:
| הוצא לאור ב: | bioRxiv |
|---|---|
| Main Authors: | , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Cold Spring Harbor Laboratory
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7402058/ https://ncbi.nlm.nih.gov/pubmed/32766589 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/2020.07.30.229377 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|